Welcome to LookChem.com Sign In|Join Free

CAS

  • or

51410-51-6

Post Buying Request

51410-51-6 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

51410-51-6 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 51410-51-6 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,1,4,1 and 0 respectively; the second part has 2 digits, 5 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 51410-51:
(7*5)+(6*1)+(5*4)+(4*1)+(3*0)+(2*5)+(1*1)=76
76 % 10 = 6
So 51410-51-6 is a valid CAS Registry Number.
InChI:InChI=1/C14H13NO2/c16-10-14(17)15-13-8-6-12(7-9-13)11-4-2-1-3-5-11/h1-9,16H,10H2,(H,15,17)

51410-51-6SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 14, 2017

Revision Date: Aug 14, 2017

1.Identification

1.1 GHS Product identifier

Product name 2-hydroxy-N-(4-phenylphenyl)acetamide

1.2 Other means of identification

Product number -
Other names -

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:51410-51-6 SDS

51410-51-6Upstream product

51410-51-6Downstream Products

51410-51-6Relevant articles and documents

Optically pure 4-aryl-2-hydroxytetronic acids

-

, (2008/06/13)

The present invention relates to a method for synthesis of optically pure stereogenically labile 4-aryl-2-hydroxytetronic acids from an optically pure aidehyde. The invention further relates to the use of such optically pure compounds as potent inhibitors of platelet aggregation by working at the level of cyclooxygenase, and additionally as inhibitors of cyclooxygenase and 5-lipoxygenase. The invention further relates to the pharmaceutical use of such.compounds in the treatment of coronary artery diseases, especially in the treatment and/or prevention of atherosclerosis, and in the treatment of various inflammatory pathologies, especially arthritis.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 51410-51-6